Company profile

Zensun (Shanghai) Sci & Tech

Recombinant neuregulin biologics for heart failure

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Recombinant human neuregulin-1 (rhNRG-1)(Neucardin)
Phase 3
ErbB2/ErbB4 (neuregulin pathway)Protein / enzyme therapeutic
Heart Failure

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.